Navigation Links
Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development

LEXINGTON, Mass., June 12, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs, announced today that Michael D. Rivard has joined the company as Vice President, Corporate Development.

Mr. Rivard has over 20 years of experience in the biotechnology industry and has held senior management positions in corporate development at ArQule, Inc., Synta Pharmaceuticals Corp., Galenea Corp., and VaxDesign Corporation.  Mr. Rivard also served as Associate Counsel (Intellectual Property) at the University of Massachusetts and as an Associate Attorney at the law firm of Palmer & Dodge (now Edwards Wildman Palmer LLP).  Mr. Rivard earned a Juris Doctor degree from the UCLA School of Law and a BA degree in biochemistry from Bowdoin College.

"I am thrilled to join this exciting company," said Mr. Rivard.  "The AVX Oral Antibody™ technology makes the gastrointestinal (GI) tract accessible to potent and safe antibody therapy.  Potential applications for our antibodies include inflammatory bowel disease (IBD), oral mucositis, GI acute radiation syndrome, celiac disease, diabetes, and any other disease which involves an antigen, soluble protein, or receptor in the GI tract or oral cavity.  The breadth of the platform offers many opportunities to work with collaborators in the pharmaceutical industry as we develop our lead product for IBD."

Barbara S. Fox, CEO of Avaxia, added, "Mike brings to Avaxia a unique mix of knowledge and experience in corporate development, intellectual property, and corporate law, as well as a scientific background.  We are confident that Mike will lead us successfully in achieving our goals of partnering our AVX-470 oral anti-TNF antibody and finding collaborators who share our vision of developing oral antibodies for other exciting targets in the GI tract."

About Avaxia Biologics, Inc.: Avaxia Biologics is developing orally administered antibody therapeutics that act locally within the gastrointestinal (GI) tract.  Antibodies are widely used as therapeutics and have nearly $50 billion in annual sales worldwide.  Ordinary antibodies are not administered orally because they are destroyed in the GI tract.  In contrast, Avaxia has developed proprietary antibodies that are stable in the GI tract.  AVX Oral Antibodies™ make disease targets in the GI tract readily accessible to antibody therapeutics.  Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes, and obesity.

SOURCE Avaxia Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
2. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
3. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
4. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... --> adds "Global Repaglinide ... "Investigation Report on China Repaglinide Market, ... forecasts data and information to its ... . --> ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... , ... Khanna Vision Institute based in Los Angeles, announced that Dr. Khanna ... Peer Certification by the Board is done so the public knows that the Doctor ... after the completion of three years of training or Residency in Ophthalmology. This is ...
(Date:11/29/2015)... ... , ... Key Housing, a top-rated corporate housing service for the San Jose ... Epic. In showcasing this featured apartment community in San Jose, Key Housing is helping ... efficiently find housing suitable to their needs by showcasing quality housing. , “San Jose ...
(Date:11/28/2015)... ... 2015 , ... Pixel Film Studios is back again with ProPanel: Pulse ... are endless. Users have full control over angle of view, speed method, start point, ... sure to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... affecting the health care in America. As people age, more care is needed, ... costs are rising, and medical professionals are being overworked. The forgotten part of ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, ... The digital component is distributed nationally, through a vast social media strategy and ...
Breaking Medicine News(10 mins):